0001520138-24-000179.txt : 20240419 0001520138-24-000179.hdr.sgml : 20240419 20240419171548 ACCESSION NUMBER: 0001520138-24-000179 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20240418 ITEM INFORMATION: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing FILED AS OF DATE: 20240419 DATE AS OF CHANGE: 20240419 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOVIE INC. CENTRAL INDEX KEY: 0001580149 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 462510769 STATE OF INCORPORATION: NV FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39015 FILM NUMBER: 24858895 BUSINESS ADDRESS: STREET 1: 680 W NYE LANE STREET 2: SUITE 201 CITY: CARSON CITY STATE: NV ZIP: 89703 BUSINESS PHONE: 775-888-3162 MAIL ADDRESS: STREET 1: 680 W NYE LANE STREET 2: SUITE 201 CITY: CARSON CITY STATE: NV ZIP: 89703 FORMER COMPANY: FORMER CONFORMED NAME: NANOANTIBIOTICS, INC. DATE OF NAME CHANGE: 20130625 8-K 1 bivi-20240418_8k.htm CURRENT REPORT
false 0001580149 0001580149 2024-04-18 2024-04-18 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported) April 18, 2024

 

BioVie Inc.
(Exact Name of Registrant as Specified in Its Charter)

 

Nevada   001-39015   46-2510769
(State or Other Jurisdiction of Incorporation)   (Commission File Number)   (I.R.S. Employer Identification No.)

 

680 W Nye Lane Suite 201

Carson City, NV

   89703
(Address of Principal Executive Offices)   (Zip Code)

 

(775) 888-3162

(Registrant’s Telephone Number, Including Area Code)

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Class A Common Stock, par value $0.0001 per share BIVI The Nasdaq Stock Market, LLC

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 
 
 
Item 3.01   Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

 

On April 18, 2024, BioVie Inc. (the “Company”) received a letter from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the bid price for the Company’s common stock for the last 30 consecutive business days had closed below the minimum $1.00 per share required for continued listing under Nasdaq Listing Rule 5550(a)(2).

 

Under Nasdaq Listing Rule 5810(c)(3)(A), the Company has been granted a 180 calendar day grace period, or until October 15, 2024, to regain compliance with the minimum bid price requirement. The continued listing standard will be met if the Company evidences a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days during the 180 calendar day grace period. In order for Nasdaq to consider granting the Company additional time beyond October 15, 2024, the Company would be required, among other things, to meet the continued listing requirement for market value of publicly held shares as well as all other standards for initial listing on Nasdaq, with the exception of the minimum bid price requirement. If measured today, the Company would qualify for Nasdaq’s consideration of an extension because the Company currently has stockholders’ equity of at least $5 million. In the event the Company does not regain compliance with the $1.00 bid price requirement by October 15, 2024, eligibility for Nasdaq’s consideration of a second 180 day grace period would be determined on the Company’s compliance with the above referenced criteria on October 15, 2024.

 

The Company is diligently working to evidence compliance with the minimum bid price requirement for continued listing on Nasdaq; however, there can be no assurance that the Company will be able to regain compliance or that Nasdaq will grant the Company a further extension of time to regain compliance, if necessary. If the Company fails to regain compliance with the Nasdaq continued listing standards, its common stock will be subject to delisting from Nasdaq.

 

Forward-Looking Statements

 

This Current Report on Form 8-K contains forward-looking statements, which may be identified by words such as “expect,” “look forward to,” “anticipate” “intend,” “plan,” “believe,” “seek,” “estimate,” “will,” “project” or words of similar meaning. In this report, forward-looking statements include, but are not limited to, the Company's ability to regain compliance with Nasdaq listing standards or receive additional time from Nasdaq to regain compliance if necessary. Although the Company believes such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be attained. Actual results may vary materially from those expressed or implied by the statements herein due to certain risks, including but are not limited to, the Company’s ability to successfully raise sufficient capital on reasonable terms or at all, available cash on hand and contractual and statutory limitations that could impair the Company’s ability to pay future dividends, the Company’s ability to complete the Company’s pre-clinical or clinical studies and to obtain approval for the Company’s product candidates, the Company’s ability to successfully defend potential future litigation, changes in local or national economic conditions as well as various additional risks, many of which are now unknown and generally out of the Company’s control, and which are detailed from time to time in reports filed by the Company with the Securities and Exchange Commission, including quarterly reports on Form 10-Q, reports on Form 8-K and annual reports on Form 10-K. The Company does not undertake any duty to update any statements contained herein (including any forward-looking statements), except as required by law.

 

 -1-

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: April 19, 2024

 

  BIOVIE INC.  
       
  By: /s/ Joanne Wendy Kim  
  Name:   Joanne Wendy Kim  
  Title: Chief Financial Officer  

 

 -2-

 EX-101.SCH 2 bivi-20240418.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 3 bivi-20240418_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 4 bivi-20240418_pre.xml XBRL PRESENTATION FILE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Cover
Apr. 18, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Apr. 18, 2024
Entity File Number 001-39015
Entity Registrant Name BioVie Inc.
Entity Central Index Key 0001580149
Entity Tax Identification Number 46-2510769
Entity Incorporation, State or Country Code NV
Entity Address, Address Line One 680 W Nye Lane Suite 201
Entity Address, City or Town Carson City
Entity Address, State or Province NV
Entity Address, Postal Zip Code 89703
City Area Code (775)
Local Phone Number 888-3162
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Class A Common Stock, par value $0.0001 per share
Trading Symbol BIVI
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 1 22 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://bioviepharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports bivi-20240418.xsd bivi-20240418_8k.htm bivi-20240418_lab.xml bivi-20240418_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "bivi-20240418_8k.htm": { "nsprefix": "bivi", "nsuri": "http://bioviepharma.com/20240418", "dts": { "schema": { "local": [ "bivi-20240418.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "inline": { "local": [ "bivi-20240418_8k.htm" ] }, "labelLink": { "local": [ "bivi-20240418_lab.xml" ] }, "presentationLink": { "local": [ "bivi-20240418_pre.xml" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://bioviepharma.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-04-18", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "bivi-20240418_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-04-18", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "bivi-20240418_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 14 0001520138-24-000179-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001520138-24-000179-xbrl.zip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bivi-20240418_8k_htm.xml IDEA: XBRL DOCUMENT 0001580149 2024-04-18 2024-04-18 iso4217:USD shares iso4217:USD shares false 0001580149 8-K 2024-04-18 BioVie Inc. NV 001-39015 46-2510769 680 W Nye Lane Suite 201 Carson City NV 89703 (775) 888-3162 Class A Common Stock, par value $0.0001 per share BIVI NASDAQ false false false false false